CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing new antibodies against botulinum neurotoxins, which pose significant bioweapon risks. It aims to create effective and safe immunotherapeutics through recombinant technology to enhance protection against these toxins.
Botulinum neurotoxins (BoNTs), the most toxic substances known, are susceptible for use as bioweapons (listed as class A agents by CDC).
Currently licensed animal derived antibodies or F(ab’)2 preparations, are at a high risk of inducing adverse effects and their privately-owned stockpiles are limited.
In this project, we will target the most lethal types of BoNTs:
A (subtypes A1 and A2), B (B1 and B2) and E (E1).
The antibodies will be directed against the C-terminus of the heavy chain and the…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
France, La Tronche
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
TECHNISCHE UNIVERSITAET BRAUNSCHWEIG
Germany, Braunschweig
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
